ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 176 filers reported holding ASCENDIS PHARMA A/S in Q4 2020. The put-call ratio across all filers is 1.39 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $118,404,971 | +22.0% | 1,264,470 | +16.3% | 0.04% | +28.1% |
| Q2 2023 | $97,061,339 | -33.3% | 1,087,522 | -19.9% | 0.03% | -36.0% |
| Q1 2023 | $145,559,084 | -11.3% | 1,357,574 | +1.0% | 0.05% | -12.3% |
| Q4 2022 | $164,094,113 | +34.2% | 1,343,602 | +13.4% | 0.06% | +23.9% |
| Q3 2022 | $122,296,000 | +57.5% | 1,184,356 | +41.8% | 0.05% | +70.4% |
| Q2 2022 | $77,640,000 | -14.2% | 835,199 | +8.3% | 0.03% | 0.0% |
| Q1 2022 | $90,477,000 | -10.6% | 770,929 | +2.5% | 0.03% | -3.6% |
| Q4 2021 | $101,207,000 | -14.7% | 752,302 | +1.1% | 0.03% | -20.0% |
| Q3 2021 | $118,584,000 | +28.7% | 743,979 | +6.2% | 0.04% | +29.6% |
| Q2 2021 | $92,142,000 | +0.5% | 700,438 | -1.5% | 0.03% | -3.6% |
| Q1 2021 | $91,639,000 | -21.4% | 711,045 | +1.7% | 0.03% | -24.3% |
| Q4 2020 | $116,569,000 | +13.5% | 698,941 | +5.0% | 0.04% | 0.0% |
| Q3 2020 | $102,740,000 | – | 665,757 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |